Benitec Biopharma Inc. announced interim clinical trial data for its BB-301 Phase 1b/2a study for the first subject treated with the Low Dose of BB-301 at the 180-Day timepoint.
AI Assistant
BENITEC BIOPHARMA INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.